Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman G.
Kaur A, et al. Among authors: venkataraman g.
Blood Cancer J. 2024 Jun 18;14(1):99. doi: 10.1038/s41408-024-01077-9.
Blood Cancer J. 2024.
PMID: 38890297
Free PMC article.